잠시만 기다려 주세요. 로딩중입니다.

희귀질환 약제, 항암제 별도 기금 도입에 대한 약제급여 결정 전문가와 이해관계자 시각

The Opinion of Experts and Stakeholder on Introduction of Orphan or Anticancer Drugs Funding Program

한국임상약학회지 2020년 30권 3호 p.177 ~ 184
김수진, 정승연, 김동숙,
소속 상세정보
김수진 ( Kim Su-Jin ) - Health Insurance Review & Assessment Service Department of Research
정승연 ( Jung Seung-Yeon ) - Korea Institute for Pharmaceutical Policy Affairs
김동숙 ( Kim Dong-Sook ) - Health Insurance Review & Assessment Service Department of Research

Abstract


Background & objective: The Korean government has expanded its benefit coverage to enhance patients' access to orphan drugs and cancer medicines. However, the number of new drugs whose indications were not applied to reimbursement in health insurance was increased. This study aimed to understand the perspectives of experts and various stakeholders on the introduction of a new funding program for cancer treatment and orphan drugs.

Methods: We conducted email surveys comprising 19 questions, from September 9 to 26, 2016. We distributed questionnaires to members of the Pharmaceutical Benefit Appraisal Committee and Cancer Assessment Committee. We also conducted a qualitative study through group interviews with stakeholders, including pharmaceutical companies and some patient groups for diseases.

Results: A total of 35 survey respondents recommended the introduction of a funding program for orphan drugs, whereas 66% recommended the launch of funding for anticancer drugs. In addition, most pharmaceutical companies and patient groups recommended the introduction of new funding programs targeting patients with cancer and rare diseases. However, some participants asserted that it would be more appropriate to modify the existing reimbursement scheme than launch new funding.

Conclusion: This study concluded that introducing new funding needs a social consensus to relieve financial hardships at the patient level.

키워드

Benefit coverage; funding; survey; interview

원문 및 링크아웃 정보

 

등재저널 정보